Nektar Therapeutics (NKTR)
70.62
-3.71
(-4.99%)
USD |
NASDAQ |
May 15, 16:00
70.70
+0.08
(+0.11%)
After-Hours: 20:00
Nektar Therapeutics Research and Development Expense (Quarterly) : 35.68M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Eli Lilly & Co. | 3.51B |
| Aquestive Therapeutics, Inc. | 4.204M |
| Boston Scientific Corp. | 516.00M |
| Esperion Therapeutics, Inc. | 8.988M |
| Corcept Therapeutics, Inc. | 66.26M |